Related Experiment Videos
DPC-423 Bristol-Myers Squibb.
1University of Naples Federico II, Department of Neuroscience, Italy. mtaglial@unina.it
Current Opinion in Investigational Drugs (London, England : 2000)
|May 22, 2002
Summary
DPC-423 is an investigational drug targeting Factor Xa, showing promise for treating thrombotic disorders. This Factor Xa inhibitor is currently in early-stage clinical trials for potential therapeutic applications.
Area of Science:
- Pharmacology
- Medicinal Chemistry
- Thrombosis Research
Background:
- Thrombotic disorders represent a significant unmet medical need.
- Development of effective anticoagulants is crucial for managing these conditions.
- Factor Xa inhibitors offer a targeted approach to anticoagulation.
Purpose of the Study:
- To introduce DPC-423, a novel Factor Xa inhibitor.
- To describe the discovery and development of DPC-423.
- To highlight its potential in treating thrombotic disorders.
Main Methods:
- DPC-423 was developed through structure-activity relationship (SAR) modifications of SN-429.
- Key modifications included replacing a benzamidine moiety with a benzylamine group.
- Analog DPC-602 was also investigated.
Main Results:
- DPC-423 is a biphenylamine-containing amide.
- It functions as a Factor Xa inhibitor.
- As of August 2000, DPC-423 had progressed to Phase I clinical trials.
Conclusions:
- DPC-423 demonstrates potential as a therapeutic agent for thrombotic disorders.
- Ongoing research and clinical trials are evaluating its efficacy and safety.
- Further investigation into DPC-423 and its analogs may lead to new anticoagulant therapies.